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Abstract: In this paper the examinations of drug eluting coronary stents are shown, such as 
the morphology of the coatings before expansion, drug distribution, the methodology and the 
value of stent retention. Surface qualities of drug coatings were examined with stereo-
microscope, metallographic microscope and scanning electron microscope. Examinations 
with confocal microscope show drug distribution in the coatings. Stent retention is a very 
important property of the stent system. Stent retention is a force, needed to the stent slip down 
from the balloon. Three drug eluting coronary stents were tested with our method. 
 




The illnesses of the 
cardiovascular system are among the 
most frequent diseases of the adult 
population in Europe. Inside of these, 
the atherosclerosis and the 
consequences of the occlusions of the 
arteries (e.g. thrombosis, heart attack 
and stroke) are the main causes of 
death, especially in the adult men 
population. The stent implantation is 
one of the most important treatments in 
the correction of the narrowed vessels 
[1,2]. 
Figure 1 shows the results 
obtained from three well known 
scientific publication databases. The 
results, which are indicated by the year 
of publishing, show that there is a dynamic development in this field possibly due to increased 
morbidity. 
 
Fig. 1 Number of papers containing the keyword 
“coated and drug eluting coronary stent” 
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2 COATING STRATEGIES 
In this paper examination of drug eluting coronary stents are shown. The application of 
coating is a possible way to combine the favourable properties of different materials. Stent 
coatings can be active or passive. While passive coatings work as a separate layer between the 
stent and the surrounding tissue due to their high biocompatibility, the active coatings inhibit 
directly the hyper-proliferation of intima. Active coatings work by the effect of the applied 
drug [3]. There are several methods to control drug release and release time for stent coatings. 
The kinetics of drug elution is a very important factor and to control it, usually some kind of 
polymer matrix were used [4,5]. 
It is possible to simple dip the stent into the agent, without polymer matrix [6]. It 
seemed useful to leave the polymer matrix because it caused inflammation. However, the 
experiments have shown that with dipping large percentage of the agent was lost during 
implantation. Another method is to apply the agent on the polymer layer, or the active 
substance can also be coated with an additional biodegradable polymer layer. This outer, 
drug-free polymer layer is very important to control the drug release because after 
implantation, in the first few days the exaggerated drug release can be very disadvantageous. 
A common method is mixing the drug with the polymer (matrix) and then coating the stent 
with this mix (Fig. 2). In these matrix devices, a drug is usually dispersed inside the polymer 
matrix, and the drug is released into the environment without any rate-controlling barrier layer 
[5]. A unique method is cutting special slots into the outer surface of the stent and these carry 
the drug (Fig. 3) [7]. The slots can carry drug or drug/polymer mix. Its drug eluting properties 
are five times better than the other stents with similar size [5,8,9]. In the reservoir devices, the 
drug reservoir is covered with a thin polymer layer (Fig. 4), which functions as a rate-
controlling membrane [5]. Another solution to produce a ceramic or polymer coating is when 
the entire coating or its outer layer has pores in it (Fig. 5), and the drug is applied into the 
pores by dipping [10]. Ion exchange based drug release can be used for controlled release of 
ionized drugs which binds to the matrix through electrostatic interactions. 
 
  
Fig. 2 Release by diffusion Fig. 3 Slots filled with polymer and drug 
  
Fig. 4 Drug loaded in stent reservoirs Fig. 5 Porous coating with drug 
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3 TESTING METHODS 
The investigations and the order of them have to be 
planned to ensure the highest possible number of test can be 
performed with a stent because coronary stents are very 
expensive tools. In our order of testing, first the destruction free 
methods (stereo- or metallographic microscopy and imaging) 
were used, these were followed by the destruction 
examinations, experiments (expansion, stent retention, etc.). 
Subsequently another destruction free method was applied 
(SEM, EDS-analysis) to study the change of the coatings. Test 
results were processed by computer and on the pictures the 
measurements were done by image analyser programs. Local 
microanalyses were done by energy dispersive x-ray detector 
mounted on the scanning electron microscope. 
Confocal microscope was used to study drug distribution. 
The tested stents were not marked with fluorescent material 
because these are complete coatings; thus we tried to use the possible autofluorescent 
properties of the coatings. In our sample autofluorescent reactions were found mostly at the 
wavelengths of 405 nm, 488 nm and 514 nm. 
Stent retention is a force, needed to the stent slip down from the balloon. To test stent 
retention, the balloon-mounted stents were fixed with an adhesive layer and placed into the 
upper clamp of the tensile equipment. In the lower clamp of the tensile equipment, the 
catheter was fixed. During the movement of the upper and lower jaws of the tensile 
equipment, the stent was pulled off from the balloon (Fig. 6).  
 
4 COATING EXAMINATIONS 
4.1 TAXUS Express
2
 stent (3.5×24 mm) 
The material of TAXUS Express
2
 stent is 316L, austenitic stainless steel (Fig. 7). The 
stent is coated with a proprietary polymer called Translute, which was developed 
specifically for the TAXUS stent. The Translute polymer is also known as SIBS 
[poly(styrene-b-isobutylene-b-styrene)]. The polymer controls the release of paclitaxel, which 
may allow for consistent drug 
release and more uniform drug 
distribution. Paclitaxel's multi-
functional effects, stabilize 
microtubules and inhibit 
activities that contribute to 
restenosis [11]. Paclitaxel is 
highly lipophilic, which may 
contribute to more uniform drug distribution [12]. This paclitaxel/polymer coating exerts its 
effect primarily in the wall of the arteries and only minimal amount of drug gets into the 
blood stream. The applied dose of drug is small but very effective, and it mostly effects when 
the restenosis appears. A portion of the drug remains in the coating. And experiments have 
found no measurable volume of drug in the body [13,14].  
In metallographic microscopic images it was observable that the coating has specific 
waving in the surface of the whole stent (Fig. 8) and polymer films between the connecting 
struts (Fig. 9). Confocal microscopy (Fig. 10) shows homogenous drug distribution. The 
green and red areas on the surface of the stent are very likely the drug particles. 
 
Fig 6 Stent retention test 
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After these destruction free examinations the retention of the stent was measured. The 
speed of this test was 5 mm/min. The stent did not slip down from the balloon during this 
experiment, the maximum force 13.6 N when the catheter was break away but the stent 
remained on the balloon. Figure 11 shows the force in function of the displacement. 
4.2 TAXUS Liberté stent (3.5×20 mm) 
TAXUS Liberté coronary stent has the same coating 
as TAXUS Express
2
 but the design of this stent is a result 
of development (Fig. 12). This stent has special design 
with flexible cells and cell distribution better simulating 
the anatomy of the artery [13,14]. 
In metallographic microscopic images it was 
observable that the coating has specific waving in the 
surface of the whole stent, like TAXUS Express
2
 stent 
(Fig. 13). The coating shows continuous films between the struts in several places and there 
were some sections where the coating lost its homogeneity (Fig. 14). The superficial 
alteration at the connections of the struts is easily observable and at these sites the coating is 
adhered more unevenly as well. The distribution of the drug was uniform (Fig. 15). After 
these destruction free examinations the retention of the stent was measured. The speed of this 
test was 5 mm/min. The stent did not slip down from the balloon during this experiment, the 
maximum force 10.9 N when the catheter was break away but the stent remained on the 
balloon. Figure 16 shows the force in function of the displacement. 
 
Fig. 12 The design of 
TAXUS Liberté stent 
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Fig. 13 The waviness of the coating of 
TAXUS Liberté stent 
Fig. 14 The polymer film between the 
struts of TAXUS Liberté stent 
 
 
Fig. 15 Drug distribution of 
TAXUS Liberté stent 
Fig. 16 Retention diagram of TAXUS 
Liberté stent 
4.3 Examination of Conor CoStar (2.5×16) stent 
The Conor CoStar stent is made of cobalt-
chromium alloy. Due to the higher strength, the stent 
has thin struts and smaller profile diameter that 
promotes easier passing through the arteries. This stent 
design incorporates small holes, each acting as a 
reservoir into which drug-polymer compositions can be 
loaded (Fig. 17). This design allows greater control of 
release kinetics. Conor CoStar stents are different from 
conventional surface-coated stents and have been 
designed specifically for drug delivery. The stent 
incorporate special structural elements called "ductile 
hinges" which absorb the mechanical stresses that occur during expansion. This stress 
absorption mechanism allows for other structural elements of the stent including the 
drug/polymer containing reservoirs to remain relatively deformation-free. Thus the reservoirs 
are largely non-deforming during stent expansion, and it is possible to use polymers in the 
reservoirs which do not have the level of elasticity, adhesion and other properties required in 
surface coatings [15]. This unique reservoir design platform contains the PLGA matrix with 
paclitaxel. Paclitaxel efficiently interferes with the proliferation of neointima hyperplasia. The 
PLGA matrix ensures the controlled drug release and drug eluting kinetics. 
 
Fig. 17 Reservoires of 
Conor CoStar stent 
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In vitro studies have shown that the matrix and drug are 
absorbed within 180 days [16,17]. A piezoelectric microdispenser 
was used to coat the reservoirs, with repeated application. The 
release of paclitaxel can be controlled easily by changing the 
degradation kinetics of the matrix [5]. 
The tested stent has a nominal diameter of 2.5 mm and a 
nominal length of 16 mm. Subsequently to the opening the sterile 
packing the stent was examined by stereo and metallographic 
microscopes. The next test was done by a confocal microscope. 
The green and red areas on the pictures are likely to show the 
drug (Fig. 18). 
Then the stent were expanded in air to their nominal 
expansion pressure (9 bar). The changing of the stent and mainly 
the surface of its coating influenced by the expansion was 
studied. The stent has three reservoirs each with different shape 
and size. The coating in the reservoirs of Conor CoStar stent remained uniform after 
expansion (Fig. 19). 
  
Fig. 19 Square shaped reservoir of 
Conor CoStar stent, after expansion 
Fig. 20 Retention diagram of 
Conor CoStar stent 
Another, but same sized stent was used to stent retention. Subsequently to opening the 
sterile packing the stent was tested by metallographic microscope and then the retention was 
measured. The speed of this test was 5 mm/min. The maximum force required was 
FRET = 4.3 N. Figure 20 shows the force in function of the displacement. 
 
5 CONCLUSIONS 
The polymer coating of TAXUS Liberté and TAXUS Express2 stents were damaged or 
uneven already before expansion. The drug dissolved uniformly on the whole surface of the 
stent but small spots with higher concentrations were also found. The waviness of the coating 
did not influence the drug distribution based on confocal microscopic images.  
The coating of Conor CoStar stent was uniform after expansion as well, although the 
cells were expanded variously. Thanks to the flexible bridges, reservoirs maintain their 
original shape even after expansion. The confocal- and electron microscopy showed that the 
drug was located mostly in the reservoirs but small spots were found on the surface as well.  
The measured value of stent retention of Conor CoStar was 4.3 N which was influenced 
by the type of coating, the material (cobalt-chromium alloy) and stent geometry. The two 
other stents did not slip down from the balloon, due to the material of the stents (316L) and 
the crimping technology. 
 
Fig. 18 Drug distribution 
and ductile hinges of 
Conor CoStar stent 
FRET 
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